Place an order request to the broker. The personal manager will contact you to confirm the order.

Order Summary

Asset: Select instrument
Quantity: -
Price per Unit: ? This price is indicative and shown for informational purposes only. The final execution price may change. -
Total Amount: -

Order Expiration

Order remains active until you cancel it or it gets filled

Order expires at the end of the selected day

Order Placed Successfully

Your order has been submitted! Our team will contact you shortly to confirm.

Order Type: -
Asset: -
Quantity: -
Total Amount: -
Manually record a past trade to keep your portfolio up to date. This helps track your P&L accurately.
Total Amount: $0.00

Trade Added Successfully

Trade recorded! Your portfolio data will be recalculated.

Type: -
Asset: -
Quantity: -
Price: -
Total: -

Chat Options

Web Search
Search the internet for recent information
Portfolio Context
Include your portfolio in the conversation
Market Data
Access real-time market information
Watchlist Context
Include your watchlist companies

Investment Managers Series Trus (IREX)

2026-10-15T19:17:05.75626+00:00

Key Updates

IREX rose +10.50% since the last report, moving from approximately $6.14 to the current $6.79, partially reversing a portion of the extreme multi-session decline previously documented (+14.65%, then -16.12%, then -10.63% in the three prior reports). Despite this intraday-to-intraday rebound, the trust fell -5.17% on the current day alone, confirming that the bounce occurred intraday/intra-period rather than representing a sustained reversal. No company-specific news was identified for IREX; the move is purely price-driven. The only available news flow concerns the broader leveraged/inverse ETF industry (Tradr fund liquidations, Yorkville MANGOS Plus leveraged launches, and Jane Street's expansion into leveraged ETF swaps), none of which directly reference IREX but provide important sector context.

Current Trend

The YTD performance remains severely negative at -77.64%, with the 6-month decline even steeper at -80.19%, indicating that the recent short-term bounce has not altered the dominant multi-month downtrend. The 1-month (-51.74%) and 5-day (-32.24%) figures confirm that losses have accelerated sharply in the most recent weeks despite the latest +10.50% recovery. The pattern across the last four reports — alternating double-digit gains and losses — shows no stable support or resistance level; each rebound has been fully or partially reversed within days. The stock continues to make lower highs on a multi-week basis, consistent with a structural collapse rather than a cyclical correction.

Investment Thesis

IREX operates within the Investment Managers Series Trust platform, a multi-issuer "white-label" structure commonly used to list leveraged, inverse, and thematic ETFs. Products of this type are designed to deliver daily-reset leveraged or inverse exposure and are explicitly marketed to sophisticated, short-term traders rather than buy-and-hold investors. The investment case for holding such an instrument rests on short-term directional conviction in the underlying reference asset combined with active, continuous position management — not on long-term capital appreciation.

Thesis Status

The thesis remains intact in describing IREX as a high-risk, short-duration trading instrument, but the extreme realized losses (-77.64% YTD, -80.19% over 6 months) confirm that the compounding/volatility-decay risk inherent to leveraged and inverse products — explicitly flagged in Yorkville's MNGB and MNGZ launch disclosures — has materially manifested. The current +10.50% rebound does not change the deteriorated thesis status; it is consistent with the high-amplitude, bidirectional volatility that characterizes decaying leveraged structures rather than a genuine recovery signal.

Key Drivers

No IREX-specific catalysts were reported. Relevant sector developments include:

  • Tradr ETFs' announced liquidation of five leveraged/inverse funds (CPNX, NXPX, PONX, SMZ, TSEU), effective October 19, 2026, highlighting rising mortality rates among niche leveraged products (PR Newswire).
  • Yorkville America's launches of the 2x Inverse (MNGB) and 2x Long (MNGZ) MANGOS Plus Daily Target ETFs, both carrying explicit warnings of potential total loss of value in a single day due to daily-reset compounding (PR Newswire, PR Newswire).
  • Jane Street's entry into the leveraged ETF swap market ($1.2bn notional in Q2 2026), indicating growing dealer infrastructure supporting this product category (Bloomberg).

Technical Analysis

IREX trades at $6.79 after a +10.50% move since the last report, but closed the current session down -5.17%, suggesting the rebound has already begun fading intraday. The security has exhibited seven-plus consecutive sessions of double-digit percentage swings in alternating directions, a pattern inconsistent with traditional support/resistance analysis. Given the magnitude of the YTD (-77.64%) and 6-month (-80.19%) declines, the instrument shows no established technical floor; prior "recovery" attempts (+14.65%) have been fully erased by subsequent declines (-16.12%, -10.63%). This behavior is characteristic of extreme volatility decay rather than a tradeable reversal pattern.

Bull Case

  • Expanding dealer participation in leveraged ETF swaps, led by Jane Street ($1.2bn notional in Q2), could improve liquidity and market-making depth for products in this category, potentially narrowing spreads for instruments like IREX (Bloomberg).
  • Continued issuer product launches (Yorkville's MNGB/MNGZ) indicate sustained institutional appetite for leveraged/inverse strategies, suggesting the broader category remains commercially viable despite individual fund volatility (PR Newswire).
  • The +10.50% rebound since the last report demonstrates that sharp, tradable relief rallies remain possible within the current volatility regime, offering tactical opportunities for active traders.
  • Persistent high daily volatility (including the current -5.17% session) indicates continued trading liquidity and market interest despite the steep cumulative decline.
  • Growing dealer infrastructure for leveraged ETF financing across the industry may provide incremental structural support that helps sustain smaller niche products over time (Bloomberg).

Bear Case

  • The -77.64% YTD and -80.19% 6-month declines represent severe, compounding capital destruction consistent with the structural decay inherent to leveraged/inverse ETF products.
  • Tradr's liquidation of five leveraged/inverse ETFs (effective October 19, 2026) signals an elevated industry-wide failure rate for niche leveraged products, raising sustainability concerns for comparable structures (PR Newswire).
  • Issuer disclosures explicitly warn that leveraged/inverse daily-reset funds "could lose all or substantially all of its value in a single day," a risk directly applicable to IREX given its realized loss profile (PR Newswire).
  • Repeated consecutive sessions of double-digit percentage swings in both directions, with no stable support level established, indicate an unpredictable price structure unsuitable for buy-and-hold positioning.
  • Daily compounding effects mechanically erode value in volatile markets regardless of underlying direction, a dynamic explicitly cited in recent leveraged ETF product documentation and consistent with IREX's extreme cumulative losses (PR Newswire).

CapPilot is AI-powered and can make mistakes. Please double-check responses.

CapPilot leverages generative AI to distill market insights and analysis, as well as answer your questions in chat. While we work hard to ensure accuracy, AI-generated content may occasionally contain inaccuracies or outdated information.

We value your feedback — reporting errors helps us continuously improve.